Better Buy: Celgene vs. Rite Aid

Before you go, we thought you'd like these...
Before you go close icon

In today's ­matchup of The Motley Fool Better-Buy Tournament, Celgene  squares off against Rite Aid  in a battle to determine which stock is the better buy now. The 64-company tournament pits two Motley Fool analysts against each other as they make the case for their stocks, with the winner determined by you, the readers.

In the video below, Motley Fool analyst Max Macaluso makes the case for Celgene, a big biotech company, to move on to the next round. After doubling in 2013, Celgene has faced a slow start to the year. However, the company's growing portfolio and pipeline make it a biotech to watch over the long term.

Motley Fool Consumer Goods editor Mark Reeth thinks Rite Aid is one of the best under-the-radar stocks on the market. A lot of people are well aware of how much the company has struggled over the last few years, but fewer know how strong the company looks today. Last year it turned a profit of $118 million, and that's on track to improve this year thanks to the company's strong pharmacy segment. This segment will also propel profits thanks to the effects of reformed health care laws, which Rite Aid is well positioned to take advantage of.

Watch these analysts square off in the video below and then vote for a winner. Then check out the other companies in the Motley Fool Better-Buy Bracket

This year's winning stock?
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Cast your vote in the poll below the video!

The article Better Buy: Celgene vs. Rite Aid originally appeared on

Mark Reeth has no position in any stocks mentioned. Max Macaluso, Ph.D., owns shares of Celgene. The Motley Fool recommends Celgene. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

People are Reading